首页> 外文期刊>Journal of nanomaterials >Evaluation of Long-Term Inflammatory Responses after Implantation of a Novel Fully Bioabsorbable Scaffold Composed of Poly-L-lactic Acid and Amorphous Calcium Phosphate Nanoparticles
【24h】

Evaluation of Long-Term Inflammatory Responses after Implantation of a Novel Fully Bioabsorbable Scaffold Composed of Poly-L-lactic Acid and Amorphous Calcium Phosphate Nanoparticles

机译:植入新型完全可吸收的聚-L-乳酸和无定形磷酸钙纳米颗粒的支架后的长期炎症反应的评价。

获取原文
获取外文期刊封面目录资料

摘要

Objectives. Our previous studies have confirmed the superior biocompatibility of the poly-L-lactic acid/amorphous calcium phosphate (PLLA/ACP) scaffolds compared to PLLA scaffolds at 1-month. In the present study, the long-term inflammatory responses of PLLA/ACP scaffolds in a porcine coronary model have been explored. Methods. The 24 PLLA scaffolds and 24 PLLA/ACP scaffolds were implanted into the coronary arteries of 24 miniature pigs. Serum levels of ALT, AST, and CRP were measured before operation, as well as 1-month, 6-months, 12-months, and 24-months. The vascular segments were taken for pathomorphological observation. HE staining was used for the inflammatory score and fibrosis score. Immunohistochemical staining detected positive expression indexes of MMP-9 and NF-κB. The expression of inflammation-related proteins of IL-1 and IL-6 was detected by Western Blot in surrounding tissues of scaffolds. Results. There was no significant difference between the two groups in ALT, AST, and UR at different time points (). The inflammation score in the PLLA/ACP group was lower than that in the PLLA group at 6-months, 12-months, and 24-months (), and the fibrosis score was reduced in the PLLA/ACP group than that in the PLLA group at 12-months and 24-months (). The expression of MMP-9 and NF-κB in the PLLA/ACP group was significantly less than that in the PLLA group at 6-months, 12-months, and 24-months (). The protein expression of IL-1 in the PLLA/ACP group was decreased than that in the PLLA group at 12-months and 24-months (). Furthermore, the protein expression of IL-1 was significantly lower than that in the PLLA group at 6-months, 12-months, and 24-months ().Conclusions. The supplement of ACP nanoparticles can effectively reduce the long-term inflammatory reaction caused by PLLA and has good safety and biocompatibility. The novel bioabsorbable PLLA/ACP scaffold provides reliable guidance for the development and clinical application of bioabsorbable scaffolds in the future.
机译:目标。我们以前的研究已经证实,与LLA支架相比,聚L-乳酸/无定形磷酸钙(PLLA / ACP)支架在1个月时具有更高的生物相容性。在本研究中,已经探索了猪冠状动脉模型中PLLA / ACP支架的长期炎症反应。方法。将24个PLLA支架和24个PLLA / ACP支架植入24只小型猪的冠状动脉。术前以及1个月,6个月,12个月和24个月时测量血清ALT,AST和CRP的水平。取血管段进行病理形态学观察。 HE染色用于炎症评分和纤维化评分。免疫组织化学染色检测到MMP-9和NF-κB的阳性表达指数。通过Western Blot检测支架周围组织中IL-1和IL-6炎症相关蛋白的表达。结果。两组在不同时间点的ALT,AST和UR之间无显着差异()。在6个月,12个月和24个月时,PLLA / ACP组的炎症评分低于PLLA组,并且PLLA / ACP组的纤维化评分较PLLA降低每组12个月和24个月()。 PLLA / ACP组在6个月,12个月和24个月时MMP-9和NF-κB的表达显着低于PLLA组。在12个月和24个月时,PLLA / ACP组的IL-1蛋白表达低于PLLA组。此外,在6个月,12个月和24个月时,IL-1的蛋白表达显着低于PLLA组()。 ACP纳米粒子的补充可以有效减少PLLA引起的长期炎症反应,具有良好的安全性和生物相容性。新型可生物吸收的PLLA / ACP支架为将来可生物吸收的支架的开发和临床应用提供可靠的指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号